Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
Feosol, Fer-In-Sol, Slow Fe; mostly generic and OTC (1) ·
Folvite; mostly generic (1) ·
Keppra (IR), Keppra XR, Spritam (3D-printed orally disintegrating), Roweepra (1) ·
Many OTC and Rx; Nascobal (intranasal); generic injection (1) ·
Microzide; mostly prescribed generically (1) ·
Pepcid, Pepcid AC, Pepcid Complete (1) ·
Trileptal (IR), Oxtellar XR (1)
classes:
[[:Category:Anticonvulsants|Anticonvulsant]] (2) ·
[[:Category:Antihypertensives|Antihypertensive]] (1) ·
[[:Category:Antisecretory_agents|Gastric acid suppressant]] (1) ·
[[:Category:B-vitamins|B-vitamin]] (2) ·
[[:Category:H2_receptor_antagonists|Histamine H2 receptor antagonist]] (1) ·
[[:Category:Hematinics|Hematinic]] (3) ·
[[:Category:Iron_supplements|Iron supplement]] (1) ·
[[:Category:Mood stabilizers|Mood stabilizer (off-label)]] (1) ·
[[:Category:Sodium channel blockers|Sodium channel blocker]] (1) ·
[[:Category:SV2A ligands|Synaptic vesicle protein 2A (SV2A) ligand]] (1) ·
[[:Category:Thiazide_diuretics|Thiazide diuretic]] (1) ·
[[:Category:Vitamins|Vitamin]] (2)
mechanism:
None (5) ·
'"`UNIQ--vote-00000138-QINU`"' Decreases urinary calcium (used in stone prevention); raises serum uric acid, glucose, and lipids modestly; non-anion-gap hypokalemic metabolic alkalosis is the characteristic electrolyte pattern'"`UNIQ--ref-00000139-QINU`"'. (1) ·
'"`UNIQ--vote-00000255-QINU`"' Less potent and shorter-acting than PPIs but with faster on-effect; suitable for on-demand acid suppression. Largely renally cleared; dose-adjust in renal impairment to avoid CNS effects (confusion in elderly)'"`UNIQ--ref-00000256-QINU`"'. (1)
uses:
'"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"' (1) ·
'"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"' (1) ·
'"`UNIQ--vote-0000013A-QINU`"', '"`UNIQ--vote-0000013B-QINU`"', '"`UNIQ--vote-0000013C-QINU`"', '"`UNIQ--vote-0000013D-QINU`"' (1) ·
'"`UNIQ--vote-00000257-QINU`"', '"`UNIQ--vote-00000258-QINU`"', '"`UNIQ--vote-00000259-QINU`"', '"`UNIQ--vote-0000025A-QINU`"' (1) ·
'"`UNIQ--vote-0000059A-QINU`"', '"`UNIQ--vote-0000059B-QINU`"' (1) ·
'"`UNIQ--vote-000005B3-QINU`"', '"`UNIQ--vote-000005B4-QINU`"', '"`UNIQ--vote-000005B5-QINU`"', '"`UNIQ--vote-000005B6-QINU`"' (1) ·
'"`UNIQ--vote-00000607-QINU`"', '"`UNIQ--vote-00000608-QINU`"', '"`UNIQ--vote-00000609-QINU`"', '"`UNIQ--vote-0000060A-QINU`"' (1)
starting dose:
0.4 mg PO daily (general prevention); 0.8-1 mg/d in pregnancy; 4 mg/d for women with prior NTD-affected pregnancy; 1 mg/d during methotrexate therapy (1) ·
12.5-25 mg PO once daily (1) ·
20 mg PO twice daily, or 40 mg at bedtime (1) ·
325 mg PO daily to TID (=65 mg elemental iron/tablet); alternate-day dosing is now favored by hepcidin physiology for better absorption with less GI burden (1) ·
Adult monotherapy: 300 mg PO BID, titrate by 300 mg every 3 days. Pediatric: weight-based titration starting 8-10 mg/kg/day divided BID (1) ·
Adult: 500 mg PO BID, titrate by 1000 mg/day every 2 weeks. Pediatric: 10-20 mg/kg/day divided BID, weight-titrated (1) ·
Replacement: 1000 mcg IM daily for 1 week, then weekly for 4 weeks, then monthly; or 1000-2000 mcg PO daily (effective even in pernicious anemia via passive diffusion); intranasal 500 mcg weekly (1)
preparations:
0.4, 0.8, 1 mg OTC; 1 mg Rx; 5 mg/mL injection (1) ·
10 mg, 20 mg, 40 mg tablets; chewables; 40 mg/5 mL oral suspension; 10 mg/mL IV (1) ·
100, 250, 500, 1000, 5000 mcg tablets (OTC and Rx); 1000 mcg/mL injection; intranasal spray; sublingual (1) ·
12.5 mg capsules; 12.5, 25, 50 mg tablets (1) ·
325 mg tablets (65 mg elemental Fe); 220 mg/5 mL liquid (44 mg elemental Fe/5 mL); 142 mg/mL drops; OTC and Rx (1) ·
IR tablets 150, 300, 600 mg; oral suspension 60 mg/mL; XR tablets 150, 300, 600 mg (Oxtellar) (1) ·
IR tablets 250, 500, 750, 1000 mg; XR tablets 500, 750 mg; oral solution 100 mg/mL; injection 100 mg/mL; Spritam ODT 250, 500, 750, 1000 mg (1)
fda max:
1 mg/d typical Rx; higher in specific indications (1) ·
160 mg/d (Zollinger-Ellison); 80 mg/d for routine indications (1) ·
2400 mg/day (adult) (1) ·
3000 mg/day (1) ·
50 mg/d (hypertension); up to 200 mg/d (edema) (1) ·
No strict ceiling; water-soluble vitamin, low toxicity (1) ·
~200 mg elemental iron/d typical practical limit (1)
routes:
onset:
1 hour PO; minutes IV (1) ·
Anticonvulsant effect within days at therapeutic plasma level (1) ·
Anticonvulsant effect within days at therapeutic plasma level; rapid titration possible (1) ·
Diuresis at 2 hours; antihypertensive effect within days, max at 3-4 weeks (1) ·
Hematologic response within days (1) ·
Reticulocyte response at 3-5 days; neurologic recovery weeks to months (and may be incomplete if longstanding) (1) ·
Reticulocyte response at 7-10 days; hemoglobin rise of ~1 g/dL per 3 weeks (1)
duration: (Click arrow to add another value)
halflife:
2.5-3.5 hours; longer in renal impairment'"`UNIQ--ref-0000025B-QINU`"' (1) ·
6-15 hours'"`UNIQ--ref-0000013E-QINU`"' (1) ·
6-8 hours'"`UNIQ--ref-0000001F-QINU`"' (1) ·
N/A (incorporated into hemoglobin and tissue stores) (1) ·
Oxcarbazepine 2 hours; '''10-monohydroxy active metabolite (MHD) ~9 hours''' (the agent that produces essentially all of the clinical effect)'"`UNIQ--ref-0000001A-QINU`"' (1) ·
~0.5 hours plasma; tissue retention longer (1) ·
~6 days (plasma); hepatic stores last 3-5 years (1)
bioavailability:
10-20% (oral; reduced by food, calcium, antacids, PPIs, tea/coffee; enhanced by ascorbate) (1) ·
40-45% (oral; not significantly affected by food)'"`UNIQ--ref-0000025C-QINU`"' (1) ·
65-75% (oral)'"`UNIQ--ref-0000013F-QINU`"' (1) ·
High (oral) (1) ·
Oral ~1-3% via passive diffusion at high doses (independent of intrinsic factor); IM/SC ~100% (1) ·
~100% (oral)'"`UNIQ--ref-0000001B-QINU`"' (1) ·
~100% (oral)'"`UNIQ--ref-00000020-QINU`"' (1)
pregnancy:
None (1) ·
'''Considered one of the safest anticonvulsants in pregnancy''', with reassuring monotherapy registry data comparable to lamotrigine and in sharp contrast to valproate, topiramate, and carbamazepine'"`UNIQ--ref-00000021-QINU`"' (1) ·
Generally considered safe; widely used. Cleared in lactation at low levels.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Routinely supplemented in pregnancy and preconception to prevent neural tube defects.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Routinely supplemented in vegan pregnancies and pernicious anemia.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Routinely used; iron requirements rise substantially in pregnancy and lactation.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Teratogenic signal less than carbamazepine but present; folate supplementation and effective contraception are appropriate in reproductive-age patients'"`UNIQ--ref-0000001C-QINU`"' (1)
legal:
OTC (10-20 mg) and [[USLegal:Prescription only|Rx-only]] (higher doses) in US (1) ·
OTC (low-dose) and [[USLegal:Prescription only|Rx-only]] (1 mg, injectable) in US (1) ·
OTC (low/mid-dose oral) and [[USLegal:Prescription only|Rx-only]] (injection, intranasal) in US (1) ·
OTC in US (1) ·
[[USLegal:Prescription only|Rx-only]] in US (2) ·
[[USLegal:Prescription only|Rx-only]] in US. Not a controlled substance'"`UNIQ--ref-00000022-QINU`"' (1)
Showing below up to 7 results in range #1 to #7.